Ondine Biomedical (OBI) Share Price, News & Analysis

Company Overview

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens. Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target. Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada.

Key Stats

• Today's Range: 10.50 to 11.50
• 50-Day Range: 7.35 to 11.50
• 52-Week Range: 4.50 to 11.90
• Volume: 131,836 shs
• Average Volume: 383,424 shs
• Market Capitalization: £31.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OBI Stock Analysis - Frequently Asked Questions

How have OBI shares performed this year?

Ondine Biomedical's stock was trading at GBX 9.50 at the beginning of 2025. Since then, OBI shares have increased by 19.7% and is now trading at GBX 11.37.
View the best growth stocks for 2025 here.

How do I buy shares of Ondine Biomedical?

Shares of OBI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Ondine Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ondine Biomedical investors own include AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX), Abacus Health Products (ABAHF) and Aurora Cannabis (ACB).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:OBI
• CUSIP: N/A
• CIK: N/A
• Web: www.ondinebio.com
• Phone: 604-669-0555
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-14,270,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -685.59%
• Return on Assets: -159.71%

Debt

• Debt-to-Equity Ratio: 1,847.37
• Current Ratio: 0.80
• Quick Ratio: 8.26

Sales & Book Value

• Annual Sales: £1.63 million
• Price / Sales: 19.35
• Cash Flow: GBX 5.71 per share
• Price / Cash Flow: 1.99
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 277,290,000
• Free Float: N/A
• Market Cap: £31.54 million
• Optionable: Not Optionable
• Beta: 0.10